Latest News

Safety Review into Alemtuzumab (Lemtrada)

April 16, 2019 | Treatments

The European Medicines Agency (EMA) announced on the 12th April it is conducting a review into the safety of MS drug alemtuzumab (Lemtrada). The EMA has launched the safety review ‘following new reports of immune-mediated conditions (caused by the body’s […]


Have your say and take our survey

June 28, 2018 | Advocacy, Support, Treatments, Uncategorised

In 2017 MSNZ officially endorsed ‘Brain Health: time matters in MS’ , an international consensus report providing recommendations on diagnosis, therapeutic strategies and improving access to treatment in MS. Since then we have used the principles to direct and provide international […]


Advocating For Increased Access to MS Treatments

June 14, 2018 | Advocacy, Research, Treatments

On Monday 28th May Multiple Sclerosis New Zealand (MSNZ) with Professor Helmut Butzkueven, of Monash University in Melbourne, met with members of PHARMAC staff to discuss our continued concerns with the very restrictive access criteria for MS disease modifying treatments […]


Ocrelizumab Funding Update

May 23, 2018 | Advocacy, Treatments

In May the minutes were released from PHARMACs Pharmacology and Therapeutics Advisory Committee (PTAC) meeting held in February 2018. At this meeting applications for funding from Roche and supporting submissions from Multiple Sclerosis New Zealand (MSNZ) were reviewed calling for […]


Ocrelizumab approved by Medsafe

December 22, 2017 | Advocacy, Treatments

Media Release – 22 December 2017 The Multiple Sclerosis Society of New Zealand (MSNZ) is pleased that Medsafe[1] has approved the registration of ocrelizumab (Ocrevus®) for both Relapsing (RMS) and Primary Progressive (PPMS) multiple sclerosis (MS) in New Zealand.   […]